deltatrials
Completed PHASE2 NCT00000770

A Comparative Study of a Combination of Zidovudine, Didanosine, and Double-Blinded Nevirapine Versus a Combination of Zidovudine and Didanosine

Sponsor: Bristol-Myers Squibb

Conditions HIV Infections
Interventions Didanosine Nevirapine Zidovudine
Updated 7 times since 2017 Last updated: Oct 27, 2021 Completion: Nov 30, 1994

Listed as NCT00000770, this PHASE2 trial focuses on HIV Infections and remains completed. Sponsored by Bristol-Myers Squibb, it has been updated 7 times since 2026, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Dec 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jan 2021 — Dec 2021 [monthly]

    Completed PHASE2

▶ Show 2 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  2. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
  • Glaxo Wellcome
  • National Institute of Allergy and Infectious Diseases (NIAID)
Data source: National Institute of Allergy and Infectious Diseases (NIAID)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Birmingham, United States, Boston, United States, Chapel Hill, United States, Charlotte, United States, Chicago, United States, Cincinnati, United States, Denver, United States, Elmhurst, United States, Greensboro, United States, Indianapolis, United States and 13 more location s